Nab-paclitaxel plus anti-PD-1 antibody as second-line treatment for advanced biliary tract cancer: An investigator-initiated phase 2 study (NapaSinti trial).

被引:0
作者
Li, Xiaofen
Zhou, Nan
Yang, Yu
Gou, Hongfeng
机构
[1] Sichuan Univ, West China Sch Clin Med, West China Hosp, Dept Abdominal Oncol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Sch Clin Med, West China Hosp, Dept Med Oncol,Gastr Canc Ctr, Chengdu, Peoples R China
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
564
引用
收藏
页码:564 / 564
页数:1
相关论文
empty
未找到相关数据